In adults with type 2 diabetes on metformin, 33% of patients on liraglutide had ultrasonographic NAFLD improvement, with no significant difference between the five drug groups.
In plain wordsIn adults with type 2 diabetes on metformin, NAFLD improved on ultrasound in 33% with liraglutide; the five drug groups did not differ significantly.
- Peptide
- Liraglutide
- Outcome
- No significant changeUltrasonographic NAFLD improvement
- Study
n = 8
- Comparator
- Gliclazide, pioglitazone, sitagliptin, exenatide
- Outcome group
- Liver fat and liver function · Liver
- Studied dose
- Dose not stated · 6 monthsAs given in this study (human).
Measurements
- Patients with ultrasonographic improvement
- 33%
- liraglutide
Source sentences
The proportions of patients who experienced ultrasonographic improvement in the different treatment groups were: 33.3% with gliclazide, 37.5% with pioglitazone, 45.5% with sitagliptin, 80% with exenatide, and 33% with liraglutide (P=.28).
2 context sentences(design, population, supporting numbers)
Prospective study of diabetic patients treated with metformin in combination with gliclazide, pioglitazone, sitagliptin, exenatide, or liraglutide.
Fifty-eight patients completed 6 months of follow-up: 15 received gliclazide, 13 pioglitazone, 15 sitagliptin, 7 exenatide, and 8 liraglutide.